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Abstract 
People with type 2 diabetes are often prescribed mul-tiple medicines which can be difficult to manage. Non-adherence to medicines can be intentional (e.g. active 
decision) or unintentional (e.g. forgetting). The objective of 
this study was to measure intentional and unintentional 
non-adherence to differing numbers of medicines pre-
scribed in type 2 diabetes. A cross sectional survey using the 
Morisky medication adherence scale (with intentional and 
unintentional non-adherence subscales) was completed by 
480 people prescribed oral antidiabetic drugs (OADs), anti-
hypertensive agents and statins. A within-subject analysis 
of variance (ANOVA) showed that intentional non-adher-
ence did not vary between OADs, anti-hypertensives and 
statins. Intentional non-adherence to statins significantly 
increased when the number of medicines prescribed was 
included as a between-subjects variable (p<0.05). Another 
within-subject ANOVA on unintentional non-adherence 
found a significant difference between OADs, anti-hyper-
tensives and statins; unintentional non-adherence to OADs 
was significantly higher (p<0.05). When the number of 
medicines was added as a between-subject variable unin-
tentional non-adherence was associated with higher num-
bers of medicines. This study shows the difference between 
intentional and unintentional non-adherence behaviours, 
and the effect that varying numbers of medicines can have 
on these behaviours.
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Background 
Co-morbid type 2 diabetes
Seventy percent of adults with type 2 diabetes also have hyper-
tension or hyperlipidaemia.1 Subsequently type 2 diabetes is 
associated with premature CVD2 and the risk of CVD mortality is 
higher for people with type 2 diabetes.3-5 Furthermore, the UK’s 
largest cause of mortality is CVD,6 and some argue that a large 
proportion of these cases are attributed to type 2 diabetes.7 
The impact of polypharmacy in co-morbid diabetes 
Large randomised controlled trials such as the United Kingdom 
Prospective Diabetes Study8 and the Collaborative Atorvastatin 
Diabetes Study9 advocate intensive pharmacological manage-
ment in type 2 diabetes. Most people with type 2 diabetes are 
prescribed multiple medicines to improve metabolic control, 
lower serum glucose, cholesterol and blood pressure10,11 
However, many studies have found that adherence is affected 
by the frequency of doses and the number of medicines pre-
scribed.12 For example, Donnan and colleagues found that 
once daily doses of OADs were associated with better adher-
ence than multiple daily doses.12,13 Few studies have examined 
the effect of multiple medicines from different drug categories. 
Our previous research has shown that people managing type 2 
diabetes and CVD may prioritise some medicines over others, 
with medicines for hyperlipidaemia management being per-
ceived as less important.14 When multiple medicines are pre-
scribed, adherence may vary between medicines as a function 
of the importance patients give them. 
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What is non-adherence?
behaviourally, performing health-promoting activities (particu-
larly medicine taking) that follow the advice of a healthcare 
professional can be defined in multiple ways. non-adherence 
and non-compliance are terms that can be applied to behav-
iours such as not initiating treatment, not taking medicines as 
prescribed and terminating treatment prematurely. the World 
Health Organisation has promoted the use of the term ‘adher-
ence’ in chronic illness, as it denotes a willingness to take 
medicines.15 the term ‘adherence’ implies that those prescribed 
medicines are intelligent, active decision-makers, independent 
and able to take an active role in the management of their 
condition.16 Adherence, like many other health behaviours, is a 
dynamic and multi-faceted concept.
Types of non-adherence to medicines
intentional and unintentional non-adherence are two types of 
non-adherence behaviours.17 intentional non-adherence is a 
behaviour driven by a decision not to take medicines. the driv-
ers of this decision are complex but have been suggested to be 
based on beliefs, personal circumstances, interpretations of 
healthcare advice and personal motivation. Unintentional non-
adherence reflects a person’s ability and skill at medicine taking 
including forgetting, poor manual dexterity, losing medicines or 
not being able to afford medicines.18 Few studies of non-
adherence in type 2 diabetes take the number of medicines 
prescribed into account, or distinguish between intentional and 
unintentional non-adherence. For example, a cross-sectional 
study showed 57% adherence to glucose-lowering medica-
tion, 64% adherence to lipid-lowering medication and 77% 
adherence to anti-hypertensive medication in participants.19 
However, this study did distinguish between intentional or 
unintentional non-adherence. intentional non-adherence may 
have played a larger role in overall non-adherence some medi-
cations. More research is needed to investigate the effect of 
different types of non-adherence across medicines prescribed 
to those with type 2 diabetes. 
Aim
the aim of this study was to examine intentional and unintentional 
non-adherence mechanisms across increasing numbers OADs, 
anti-hypertensives and statins in patients with type 2 diabetes. 
Method
Cross-sectional data were collected from a postal questionnaire 
and medical records between September 2007 and March 
2008. this study was approved by a local national Health 
Service Research ethics Committee in May 2007 (reference 
number 07/Q1410/28).
Participants 
eight hundred and seventy-eight people with type 2 diabetes and 
CVD were identified from a secondary care diabetes database. 
Adult patients (aged 18 years and over) were included if they were 
prescribed one or more OAD, one or more anti-hypertensive, 
and a statin. People with a care or nursing home address were 
excluded as they were assumed to have less personal control over 
taking their medicines than community dwelling populations. 
People who had not attended the diabetes clinic at the hospital 
where the study was undertaken within 12 months of the study 
starting were not approached. this technique improved the 
response rate and ensured that people were not sent mail from 
healthcare services with which they had little or no contact. 
Materials 
the number of medicines prescribed for type 2 diabetes, hyper-
tension and hyperlipidaemia was extracted from the local hos-
pital’s diabetes register. the number of medicines prescribed 
was categorised as 3, 4 or 5, and >6. 
intentional and unintentional non-adherence across OADs, 
anti-hypertensives and statins was assessed using the Morisky 
Medication Adherence Scale (see table 1). A five-point Likert 
scale was used with scores ranging from 0 (total adherence) to 
4 (indicating non-adherence). the Morisky scale measures self-
reported intentional (two items) and unintentional (two items) 
non-adherence to medicines.20 this was repeated three times; 
once for OADs (as shown in table 1), once for anti-hyperten-
sives and once for statins. therefore, the individual drivers of 
intentional and unintentional non-adherence for each category 
of medication could be assessed. 
A questionnaire was also used to collect demographic 
information. the Morisky scale, the demographic information 
scale and a pre-paid return envelope were posted to potential 
participants. 
Procedure 
the collaborating diabetologist with consent to access patient 
medical records used the eligibility criteria to identify eligible adults 
from the diabetes register based on the medicines prescribed. the 
diabetes register incorporated prescribing information from sec-
ondary and primary care to enhance the quality of data obtained. 
the Morisky medication adherence scale, a participant information 
Table 1.   the four item Morisky medication adherence scale adapted 
for type 2 diabetes20*
 Morisky questionnaire item 
item 1 Do you ever forget to take your diabetes medicines?
item 2  Are you ever careless at times about taking your
diabetes medicines?
item 3  When you feel better do you sometimes stop taking
your diabetes medicines?
item 4  Sometimes, if you feel worse when you take your
diabetes medicines, do you stop taking them?
*the Morisky questionnaire was repeated three times; once for oral 
antidiabetic drugs, once for anti-hypertensive agents and again for 
statins.
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sheet and an invitation letter were sent to eligible subjects. Data 
from the questionnaires completed and returned were entered 
into an SPSS database (version 15).21 
Analysis 
A repeated measures AnOVA was used to test the hypothesis 
that intentional and unintentional non-adherence would differ 
between categories of medicines prescribed for type 2 diabetes 
and CVD: this was the within-subjects analysis. the ‘categorical 
number of medicines’ variable was used as a between-subjects 
variable. the between-subject effect of the number of medi-
cines prescribed was examined across the repeated measures 
analyses for intentional and unintentional non-adherence.
Results 
Response rate
Following the first mailing two reminders were sent to increase 
the response rate, each two weeks apart from one another. the 
first mailing directly approached 855 people and 480 question-
naires were returned after three postal mailings (one initial 
mailing and two reminders). Forty-two people returned a blank 
questionnaire or declined participation directly. the final 
response rate for this study was 56% (n=480). 
Demographics
Participants’ mean age was 66.3 years (range: 28–94 years), 
with 64.6% male (data were missing in three cases); 91.7% 
white, 1.8% Asian, and 0.4% from other backgrounds. Data on 
ethnicity were missing for 25 cases. table 2 shows the range of 
medicines prescribed to participants. nearly one fifth (21.5%) of 
participants reported that their annual household income was 
less than £19,999, 7.9% reported that their annual income 
was above £20,000, 42.9% choose not to disclose their annual 
household income and 27.7% reported that they were retired. 
Over one third (35.4%) of participants reported that they had 
no educational qualifications. GCSes and A levels<AQ2> were 
reported to be the highest educational achievement by 15.8% 
of participants whilst 8.9% had achieved a HnD qualification 
or undergraduate degree, 0.6% had achieved a postgraduate 
qualification and 39.2% of people did not report their highest 
educational achievement. 
Rate of total adherence across medication categories 
Overall, across medicines, levels of intentional (deliberate) 
non-adherence were lower than unintentional (accidental) 
non-adherence. the percentage of people who did not report 
any level of unintentional non-adherence to OADs was 37.1% 
(n=178); for anti-hypertensives the percentage of people 
reporting no level of unintentional non-adherence was 52.9% 
(n=254) and no level of unintentional non-adherence to 
statins was 53.1% (n=255). the percentage of people who 
reported no intentional non-adherence was 86.9% (n=417) 
for OADs, 80.8% (n=388) for anti-hypertensives and 81.9% 
(n=393) for statins. 
Unintentional non-adherence 
the within-subject effect for unintentional non-adherence 
across medicines was significant F(2,409) = 20.201, p≤0.001, 
partial eta squared = 0.090). Unintentional non-adherence 
significantly varied between OADs, anti-hypertensives and 
statins. therefore, unintentional non-adherence was higher for 
some medicines than for others. Post-hoc analyses revealed 
that the difference in unintentional non-adherence between 
OADs and anti-hypertensives was significant (mean difference 
= 0.404, p≤0.001, Ci(95%) 0.288–0.521); unintentional non-
adherence to OADs was higher. Unintentional non-adherence 
was significantly higher for OADs when compared with statins 
(mean difference = 0.341, p=0.000, Ci(95%) 0.209–0.474). 
the difference between unintentional non-adherence to anti-
hypertensives and statins was not significant (mean difference 
= -0.063, p=0.287, Ci(95%) -0.181 to -0.056)<AQ3>. For 
people prescribed multiple medicines for type 2 diabetes, unin-
tentional non-adherence to OADs was found to be significantly 
higher than for any other prescribed medicines. 
Participants were allocated to groups based on the number 
of medicines prescribed: 232 people were prescribed three 
medicines; 102 people were prescribed four or five medicines; 
146 people were prescribed six or more medicines. these cat-
egories formed the between-subjects variable. 
When the between-subjects variable was added to the 
analysis of unintentional non-adherence the number of medi-
cines prescribed was found to have a significant effect (F(2,410) 
= 3.010, p=0.050, partial eta squared = 0.014). Unintentional 
non-adherence decreased as the number of medicines pre-
scribed increased (see figure 1) but the interaction was not 
Table 2.  numbers of participants prescribed each medication
Category  Name of Number (%)  
of medication medication prescribed 
 sub-category
Oral antidiabetic Metformin  388 (80.33%) 
drugs thiazolidinediones  74 (15.42%)
Anti-hypertensives Angiotensin i 324 (67.50%) 
 converting enzyme 
 (ACe) inhibitors
 Calcium channel 211 (43.96%) 
 blockers
 Angiotensin ii 128 (26.67%) 
 receptor antagonists
 Diuretics 126 (26.25%)
 Alpha-blockers  49 (10.21%)
HMG CoA reductase inhibitors (statins) 480 (100%)
Sulphonylureas and beta-blockers had not been prescribed to study 
participants
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significant (F(4,818) = 0.744, p=0.562), therefore, the between-
subjects effect was consistent across all categories of medi-
cines; no one medicine type was particularly affected by the 
number of medicines prescribed. <AQ3> 
Intentional non-adherence 
the repeated measure AnOVA measuring the within-subject 
effect for intentional non-adherence was not significant 
(F(2,410) = 2.437, p=0.890) therefore intentional non-adher-
ence did not vary between categories of medicines prescribed 
for type 2 diabetes with CVD. <AQ3>
the between-subjects effect was not significant (F(2,411) = 
2.028, p=0.133). therefore, intentional non-adherence did not 
differ in participants prescribed more medicines. the interac-
tion was significant (F(4,820) = 2.427, p=0.046, partial eta 
squared = 0.012) with intentional non-adherence to statins 
changing as six or more medicines were prescribed. this means 
that for those taking larger numbers of medicines more deci-
sions not to take statins were made (see figure 2); but this 
effect did not occur for OADs or anti-hypertensive medicines. 
<AQ3>
Discussion
the key finding of this study is that a significant difference in 
unintentional non-adherence was found between OADs, anti-
hypertensives and statins. Unintentional non-adherence was 
higher for OADs than anti-hypertensives and statins, while anti-
hypertensives and statins had similar levels of unintentional 
non-adherence. 
this study found that unintentional non-adherence 
decreased as more medicines were prescribed, suggesting that 
forgetting decreased for those prescribed greater numbers of 
medicines. Furthermore, this effect was consistent across all 
categories of medicines. the possible reason for this finding is 
that increased vigilance exists among people managing high 
numbers of medicines. the use of dosette boxes, greater con-
tact with healthcare professionals and greater disease severity 
may be factors which influence this finding. the range of strat-
egies to manage regimen complexity has been reported else-
where;22,23 it is likely that people used a range of strategies to 
facilitate adherence in this complex regimen too. Precise exam-
ination of these strategies may help improve adherence in 
complex regimens. 
Previous research has drawn the distinction between inten-
tional and unintentional non-adherence. Our research suggests 
that people with type 2 diabetes and CVD prescribed multiple 
medicines may vary in their unintentional non-adherence, with 
medicines for type 2 diabetes being the most likely to be for-
gotten. Less variance between medicines was observed for 
intentional non-adherence, however, when the number of 
medicines prescribed was high greater variance was observed, 
particularly around taking statins. this study shows that delib-
erate and accidental non-adherence varied by the number of 
medicines prescribed, with deliberate non-adherence increas-
ing for statins only, and accidental non-adherence decreasing 
as more medicines were prescribed. 
Unintentional non-adherence was higher for OADs; this 
may be because medicines for type 2 diabetes are more likely 
to be prescribed as multiple doses. the increased number of 
doses for OADs may have increased missed doses; further 
research should examine whether people have difficulties man-
aging midday doses (possibly because of work or social com-
mitments). Further research should also focus on whether the 
differences in intentional and unintentional non-adherence are 
maintained when daily doses as opposed to the number of 
medicines prescribed are examined.
Figure 1.   Unintentional non-adherence across medicines for participants 
prescribed at least three medicines
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Figure 2.   intentional non-adherence across medicines for participants 
prescribed at least medicines 
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As more medicines were prescribed, non-adherence to 
statins increased in this study; statins were the only medication 
to remain consistent across the sample obtained; all partici-
pants were prescribed one type of statin. OADs and anti-
hypertensives did increase in number, but remained unaffected 
by non-adherence decisions. Statins appear to be vulnerable to 
non-adherence decisions when increasing numbers of medi-
cines are prescribed. Our previous research found that OADs 
and hypertensive medicines are prioritised above statins by 
patients. it seems as regimens become more complex then 
medicines which are undervalued become more vulnerable to 
non-adherence.14 Clinicians should recognise that by intensify-
ing the management of type 2 diabetes by increasing OADs or 
anti-hypertensives, adherence to statins may be compromised.
Limitations
the participants were from a narrow range of ethnic back-
grounds, limiting the generalisability of these findings. the sam-
ple was drawn from a population of largely elderly people (mean 
age 66.3 years) who had a range of long-term conditions. the 
focus of this investigation was type 2 diabetes and CVD but the 
people who participated may have been taking other medicines; 
therefore, the presence of other co-morbidities may have influ-
enced the way medicines were managed for some participants. 
in addition, there are limitations in the use of self-report measures 
to examine adherence; over-reporting of non-adherence may 
have been a problem. Also, some participants may have felt 
threatened by they way that questions on the Morisky adherence 
scale are phrased. For example, one question indicates careless-
ness, which could be interpreted by participants as an accusation 
or culpability for poor self-management. the potential for ques-
tionnaire items to generate negative feeling among participants 
may have led to underreporting of non-adherence on some ques-
tionnaire items. Hypothetically there may be implications of 
repeating questions on non-adherence for three types of medi-
cines. However, further research is needed to examine the effect 
of repeated questioning on the reliability and validity of responses 
to adherence items. 
Future research should make attempts to distinguish between 
intentional and unintentional non-adherence and specify which 
type of adherence is being measured. 
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Key messages 
 
● intentional and unintentional non-adherence are differ-
ent behaviours 
● Unintentional non-adherence differs between medicines 
● intentional non-adherence differs between increasing 
numbers of medicines 
